ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

NEWG Newgen BioPharma Corporation (CE)

0.000001
0.00 (0.00%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Newgen BioPharma Corporation (CE) USOTC:NEWG OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.000001 0.00 01:00:00

Current Report Filing (8-k)

19/09/2016 9:56pm

Edgar (US Regulatory)


 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported):  September 19, 2016

 

GREENWIND NRG INC.

 (Exact Name of Registrant as Specified in its Charter)

 

 

Nevada

 

000-1537274

 

N/A

(State or other jurisdiction of incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

 

 

3221 Dominquez Avenue, Quezon City, Philippines

 

N/A

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: 855-624-4793

 

Former Name or Former Address, if Changed Since Last Report:

N/A

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[  ]

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[  ]

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[  ]

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[  ]

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 
 

 

Section 8 – Other Events

 

Item 8.01 Other Events.

 

On September 19, 2016, upon completion of processing from the Financial Industry Regulatory Authority (FINRA), Greenwind NRG Inc. (the “Company”) effected a 4for 1 forward stock split of all of its issued and outstanding shares of common stock (the “Stock Split”). The Board of Directors of the Company had approved the Stock Split on September 1, 2016. The Stock Split increases the number of the Company’s issued and outstanding common stock to 47,600,000, from the current 11,900,000.   The Stock Split will not affect the number of the Company’s authorized common stock or its par value, which remain at 75,000,000 and $0.001 par value per share, respectively.

 

 

 
2
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Greenwind NRG Inc.

 

a Nevada Corporation

 

       
Dated:  September 19, 2016 By

/s/ Jerwin Alfiler

 

 

Jerwin Alfiler

 
    President  
       

 

 
3

 

 

1 Year Newgen BioPharma (CE) Chart

1 Year Newgen BioPharma (CE) Chart

1 Month Newgen BioPharma (CE) Chart

1 Month Newgen BioPharma (CE) Chart

Your Recent History

Delayed Upgrade Clock